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Summary The exposure of cells to 06-benzyl-N2-acetylguanosine (BNAG) and several guanine derivatives is known to reduce the activity of
06-alkylguanine-DNA alkyltransferase (MGMT) and to enhance the sensitivity of Mer+ (methyl enzyme repair positive) tumour cells to
chloroethylnitrosoureas (CENUs) in vitro and in vivo. High water solubility and the pharmacokinetic properties of BNAG make it a candidate
for simultaneous administration with CENUs by the i.v. route in human clinical use. In vivo we have shown previously that BNAG significantly
increases the efficiency of N'-[2-chloroethyl]-N-[2-(methylsulphonyl)ethyl]-N'-nitrosourea (cystemustine) against M4Beu melanoma cells
(Mer+) through its cytostatic activity by the i.p. route, but also increases its toxicity. To investigate the toxicity of BNAG and cystemustine when
administered simultaneously in mice, we compared the maximum tolerated dose and LD50 doses of cystemustine alone or in combination with
40 mg kg-1 BNAG by the i.p. route. The toxicity of cystemustine was enhanced by a factor of almost 1.44 when combined with BNAG. To
compare the therapeutic index of cystemustine alone and the cystemustine/BNAG combination, pharmacological tests were carried out in
nude mice bearing Mer+ M4Beu human melanoma cells. Isotoxic doses were calculated using the 1.44 ratio. The treatments were
administered three times by the i.v. route on days 1, 5 and 9 after s.c. inoculation of tumour cells. Although the toxicities of the treatments
were equal, BNAG strongly enhanced tumour growth inhibition. These results demonstrate the increase of the therapeutic index of
cystemustine by BNAG and justify the use of BNAG to enhance nitrosourea efficiency in vivo by i.v. co-injection.
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Chloroethylnitrosoureas (CENUs) are cancer chemotherapeutic
drugs widely used in the treatment of several tumours, in particu-
lars brain, systemic malignancies and melanomas. However, in
most neoplasms, the response rate is relatively low after single-
agent chemotherapy -about 20% in disseminated melanomas (Lee
et al, 1995). CENUs are bialkylating agents and act through the
formation of a chloroethyl cation that is able to react on several
nucleophilic sites ofthe nucleic acids. The main cytotoxic lesion is
06-chloroethylguanine, which is able spontaneously to form cova-
lent cross-links with the complementary DNA strands (Tong et al,
1983; Lemoine et al, 1991). However, the suicidal DNA repair
protein 06-alkylguanine-DNA alkyltransferase (MGMT; EC
2.1.1.63) removes O6-alkylguanine by accepting the alkyl group
on the cystein residue of its active site (D'Incalci et al, 1988;
Lindahl et al, 1988; Pegg and Byers, 1992). This protein is respon-
sible for the chemoresistance oftumour cells towards CENUs and
methylating agents (Nagane et al, 1992; Mineura et al, 1993;
Gerson and Willson, 1995; Pegg et al, 1995). Its amount in the cell
is inversely proportional to the DNA interstrand cross-links
frequency and consequently to cell sensitivity to CENUs
(Godeneche et al, 1990). The constitutive level of MGMT in




mammals varies considerably from species to species but also
from tissue to tissue within the same species (Pegg et al, 1995). A
wide MGMT spectrum has been found in neoplasic tissues: cells
that exhibit high MGMT levels have been designated Mer+ (Mer
for methyl enzyme repair) and those that are MGMT deficient as
Mer-. It has been shown previously that O6-benzylguanine (BG)
can significantly decrease the MGMT activity of Mer+ cells
through its ability to act as a substrate for the protein (Dolan et al,
1990a; Moschel et al, 1992; Pegg et al, 1993). This property has
been used to increase the Mer+ cell sensitivity to CENUs (Dolan et
al, 1991; Baer et al, 1993; Mineura et al, 1994). In vivo studies
conducted on nude mice bearing Mer+ human colon or glioma
tumours have shown that treatment with BG before administration
of a bialkylating agent significantly inhibited tumour growth
compared with animals treated with BG or a bialkylating agent
alone (Dolan et al, 1990b; Friedman et al, 1992; Mitchell et al,
1992; Gerson et al, 1993). A phase I clinical trial of BG with
carmustine is in progress (Spiro et al, 1996). Nevertheless, its
clinical use can be problematic because of its very low water
solubility, and new MGMT inhibitors have accordingly been
developed that are more water soluble (Cussac et al, 1994a;
Schold et al, 1996).
To address this problem, we have synthesized N2-acetylguano-
sine and deoxyguanosine derivatives that are benzylated on the 06
position. The sugar moiety makes these species highly water
soluble and the acetylation of the amine function should render
pairing with the complementary base and the incorporation into
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Table 1 Maximum-tolerated dose and LD50 of cystemustine and/or BNAG






40 mg kg-' BNAG
Ratio 1.44 1.45
Cystemustine 33.3 mg kg-' + BNAGa 80 260
aVariable doses. bDose (mg kg-1). Maximum-tolerated dose, highest dose
administered without toxicity over the test. LD50 was determined according to
Behrens and Karber.
DNA much more difficult. In previous work, BNAG and 06_
benzyl-N2-acetyldeoxyguanosine (BNAdG) have been tested for
the potentiation of the cytotoxic effect of a new CENU, N'-[2-
chloroethyl]-N-[2-(methylsulphony)ethyl]-N'-nitrosourea (cyste-
mustine). This CENU was developed by us and is currently being
used in melanoma and glioma clinical phase II trials of the
European Organization for Research into the Treatment ofCancer
(Madelmont et al, 1985; Bourrut et al, 1986; Mathe et al, 1992;
Godeneche et al, 1994). We have shown that both BNAG and
BNAdG significantly increased the cytotoxicity of cystemustine
towards M4Beu human melanoma tumourcells (Mer+) through the
inhibition of MGMT. Preliminary in vivo anti-tumour tests on
nude mice bearing M4Beu xenografts showed an increased inhibi-
tion of tumour growth by cystemustine in combination with
BNAG but also an increased toxicity (Cussac et al, 1994a). To
investigate interactive phenomena between cystemustine and
BNAG, a pharmacokinetic study of BNAG i.v. bolus was
performed using 14C labelling (Madelmont et al, 1992; Cussac et
al, 1994b). We showed that only 10% ofthe administered dose was
metabolized and that the unchanged molecule had a rapid and
wide distribution in all tissues except the central nervous system.
Moreover, an enterohepatic cycle with a slow elimination rate
extends the half-life of the molecule in the organism. From these
pharmacokinetic characteristics, it is highly probable that MGMT
inhibition, after an i.v. bolus, occurs promptly and is maintained
for a long time after administration. Comparison with pharmaco-
kinetic properties of cystemustine (Godeneche et al, 1987) indi-
cates that a simultaneous i.v. injection of this CENU with BNAG
should be the optimal administration schedule. In this work, our
purpose is to compare the therapeutic index for the simultaneous
administration of the BNAG/cystemustine combination with
cystemustine alone in nude mice bearing resistant human
melanoma. After measurement of the LD50 of BNAG, cystemus-
tine and the combination ofBNAG/cystemustine, the effectiveness
oftreatments at isotoxic doses are compared.
METHODS
Drugs
Cystemustine was synthesized by usual procedures (Madelmont et
al, 1991) and BNAG was synthesized by procedures previously
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Figure 1 Tumour growth inhibition and toxicity after high-dose i.v.
treatment. M4Beu cells (4 x 106) suspended in PBS were inoculated s.c. on
day 0. Mice were treated on days 1, 5 and 9 by sterile sodium chloride 0.9%
solution (A, Tol), BNAG 50 mg kg-' (0, To2), cystemustine 18.75 mg kg-'
(C, To3), cystemustine 27 mg kg-' (-, To4) and cystemustine 18.75 mg kg-'
+ BNAG 50 mg kg-' (0 To5) by the i.v. route. (A) Tumour volume of M4Beu
xenografts - the mean tumour volume + s.e.m. (bars) is represented. (B)
Weight loss of mice after high-dose i.v. treatment - the mean weight loss is
represented
Cells culture
M4Beu, a human melanoma cell line was derived from metastatic
biopsy specimens and had been maintained in cell culture for
almost 20 years at the Institute National de la Sante et de la
Recherche Medicale, Unit 453, Centre Leon Berard, Lyon, France
(department ofDrJFDore). Stock cell cultures were maintained as
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Table 2 Effects of cystemustine and BNAG combination at high dose in nude female mice bearing M4Beu tumour cells
Treatment Tumourweight at day 30 Tumour volume at day 30 Maximum body weight Number of deaths/number
mean ± s.d. (mg) mean ± s.d. (mm3) loss mean (limit values) of treated mice
(statistical significance) (statistical significance) (% day 1)
(statistical significance)
To1 396 ± 206 759± 145 None 0/8
(S4**) (S4 )
To2 443±223 990± 183 None 0/8
(NS,; S4**) (NS1; S41
To3 54 ± 36 184 ± 49 5.2 (4.2-8.7) on day 9 0/8
(NS,; NS4) (SI*; NS4) (S4**)
To4 51 ± 25 205 ±43 12.5 (4.5-16.7) 1/8
(NS,) (S,*) on day 12 on day 7
To5 8 7 54 ± 19 11.3 (2.2-18.2) 1/8
(S,*; S4*) (S,*; S41) on day 9 and 12 on day 7
(NS4)
Eight mice per group were treated on days 1, 5 and 9 after M4Beu cells inoculation by a single i.v. injection of sodium chloride 0.9% (Tol), BNAG
50 mg kg-' (To2), cystemustine 18.75 mg kg-' (To3), cystemustine 27 mg kg-' (To4) and cystemustine 18.75 mg kg-' with BNAG 50 mg kg-1 (To5). Statistical
analysis was performed according to the Mann-Whitney U-test for tumour weight, volume and body weight loss. (N)S,, (no) significant difference compared with
Tol. (N)S4, (no) significant difference compared with To4. (*P< 0.05, **P< 0.01).
monolayers in 75 cm2 culture flasks in Eagle's minimum essential
medium (Gibco, Paisley, UK) supplemented with 10% fetal calf
serum (Sigma, St Louis, USA) and solutions of5 ml of IOOX vita-
mins (Gibco), 5 ml of 100 mm sodium pyruvate (Gibco), S ml of
IOOX non-essential amino acids (Gibco), 5 ml of200 mM L-gluta-
mine (Gibco) and 2 mg ofgentamycin base (Gentalline, Schering-
Plough, Levallois-Perret, France). Cells were grown at 37°C in a
humidified atmosphere containing 5% carbon dioxide. M4Beu
cell-doubling time was 24 h.
Toxicity assessment
OFI female mice 5-7 weeks old (Iffa-Credo, L'Abresle, France)
were randomly assigned to five groups of six mice (20-25 g) for
each compound tested and treated once with cystemustine and/or
BNAG by the i.p. route at 0.5 ml per 25 g. Both drugs were
dissolved in sterile sodium chloride 0.9% with 2-7% ofdimethyl-
sulphoxide (DMSO), vehicle which showed no toxicity in the
preliminary test (data not shown). The doses of cystemustine
ranged from 40 to 82.8 mg kg-' or from 27.8 to 57.6 mg kg-' with
a ratio of 1.2 between increasing doses to determine the LD50 of
cystemustine alone or in combination with BNAG 40 mg kg-'
respectively. The doses of BNAG ranged from 40 to 640 mg kg-'
with a ratio of2. Mice were weighed daily; when animals had loss
of weight more than 25% or when they were expected to become
moribund, according to the guidelines of UKCCCR (UKCCCR
committee, 1988), they were sacrified by decapitation. On day 8
after administration, the LD50 was calculated using the simplified
method ofBehrens and Karber (1935).
In vivo anti-tumour tests
Swiss nu/nu female mice 6-7 weeks old (Iffa-Credo) were inocu-
lated with 4 x 106 M4Beu cells by abdominal s.c. injection. One
day later, animals wererandomly assigned into five groups ofeight
mice and treated by i.v. route (tail vein) with cystemustine and/or
BNAG at 0.3 ml per 25 g. Both drugs were dissolved in sterile
sodium chloride 0.9% at several doses as indicated in the figures.
After treatment, animal weight and tumour dimensions were
determined twice a week. Tumourdimensions were measured with
callipers and tumour volume was calculated using the formula
length x width2 x 0.5 (Dolan et al 1990b).
At the end of each test, the animals were sacrificed and the
xenografts were removed and weighed. Toxicity was assessed
by survival and maximum body-weight loss. Tumour volume,
tumour weight (only for the first test) and body-weight loss
comparisons according to the treatment were performed using the
Mann-Whitney U-test.
RESULTS
The acute toxicity ofa single i.p. injection ofBNAG alone, cyste-
mustine alone or the combination of BNAG/cystemustine was
evaluated on OFI female mice according to Behrens and Karber
(Table 1). BNAG showed no toxicity as no death nor loss of
weight were observed at the maximal dose used (640 mg kg-').
The LD50 values ofcystemustine with and without BNAG (40 mg
kg-') on day 8 were 47.2 mg kg-' and 68.2 mg kg-' respectively. In
both cases, the signs oftoxicity were loss ofweight, diarrhoea and
asthenia. Maximal toxic effect occurred 6 days after injection with
the different treatments. The ratios ofmaximal-tolerated dose and
LD50 for cystemustine alone or in combination with BNAG were
almost constant and were close to 1.44. To determine whether
BNAG had a dose effect on the toxicity of33.3 mg kg-' cystemus-
tine, the toxicity of the combination was assessed with increased
doses ofBNAG. LD50 was obtained with 260 mg kg-' ofBNAG.
To compare the therapeutic index of the combination with that
of cystemustine alone, two in vivo anti-tumour tests were
performed by i.v. route. The experimental model was Swiss nu/nu
female mice bearing abdominal s.c. human melanoma M4Beu
cells. This tumour line has a high MGMT activity (933 fmol mg-'
of protein) and was strongly resistant to cystemustine (Cussac et
al, 1994a). The equitoxic doses ofcystemustine alone or in combi-
nation with 40 or 50 mg kg-' BNAG were determined assuming
the linear increase ofcystemustine toxicity at all doses ofBNAG.
The dose ratio between cystemustine alone and in combination
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Figure 2 Tumour growth inhibition and toxicity after low-dose i.v. treatment.
M4Beu cells (4 x 106) suspended in PBS were inoculated s.c. on day 0. Mice
were treated on days 1, 5 and 9 by sterile sodium chloride 0.9% solution
(A, Thl), BNAG 40mg kg-' (0, Th2), cystemustine 15mg kg-' (O, Th3),
cystemustine 21.6 mg kg-' (U, Th4) and cystemustine 15 mg kg-' + BNAG
40mg kg-' (0, Th5) by the i.v. route. (A) Tumour volume of M4Beu
xenografts - the mean tumour volume + s.e.m. (bars) is represented.
(B) Weight loss of mice - the mean weight loss is represented
with BNAG was taken to be equal to 1.44, and this value was used
to determine the calculated isotoxic dose.
In the first test (To), we chose a large dose to observe both
tumour growth inhibition and toxic effect. Tumours appeared
within 6 days in all groups ofmice despite treatment and grew with
different kinetics (Figure IA). No xenograft growth was observed
with the cystemustine 18.75 mg kg-' and BNAG 50 mg kg-' (ToS)
combination treatment. On day 30, when the mean tumour volume
in the BNAG 50 mg kg-' (To2)-treated group reached approxi-
mately 1000 mm3, the test was stopped for all groups. T'umour
volume and weight were used for the statistical comparison
between the vehicle (To1)-treated or cystemustine 27 mg kg-' dose
(To4)-treated groups (Table 2). The effect ofthe To2 treatment was
not significantly different from that of the control (P = 0.38).
Cystemustine 18.75 mg kg-' (To3) and To4 treatment was signifi-
cantly different from control for tumour volume (P = 0.014 and
P = 0.021 respectively). No significant dose-dependent difference
was observed on tumour growth inhibition between the two treat-
ments (To3 or To4) (P = 0.71). In contrast, the To5 treatment was
significantly more effective in inhibiting tumour growth than the
To3 or To4 treatments (P = 0.026 and P = 0.007 respectively).
The toxicity of the treatment was assessed by the number of
deaths per group over the test, the maximum weight loss and the
weight loss kinetics (Figure iB). Tol and To2 treatment showed
no toxicity. To3 and To4 were toxic with an increased To4 effect
that was lethal on day 7 in one case. Toxic signs were the same as
those described above. Association of BNAG with cystemustine
demonstrated an increased toxic effect compared with cystemus-
tine alone, but the number of dead mice and the maximum weight
loss were the same in the two calculated isotoxic dose treatments
To4 and To5.
In the second test (Th), we chose a lower dose of drug to
monitor only the pharmacological effect of the treatment. We
stopped this test for each group as soon as tumour growth was
evident for all mice. Tumours appeared within 5 days in all groups.
Tumour growth kinetics were different for each treatment (Figure
2a). Tumour began to grow within 9 days for vehicle (Thl)- and
BNAG 40 mg kg-' (Th2)-treated mice. Cystemustine alone
increased growth delay for the two tested doses. Mean tumour
volume increased on day 16 for cystemustine 15 mg kg-' (Th3)
treatment and on day 26 for cystemustine 21.6 mg kg-' (Th4); for
both, the growth kinetics were equivalent. BNAG 40 mg kg-' and
cystemustine 15 mg kg-' (ThS) treatment prevented tumour
growth for up to 43 days as shown in Figure 2a. To assess whether
the tumour was potentially able to grow, we kept the latter group
of mice for an additional 20-day period. Tumours grew between
day 49 and 63 for six out of the seven mice (data not shown).
Tumour volumes on day 29 and on day 43 were used for statistical
comparison (Table 3). On day 29, tumour volumes were not signif-
icantly different between the Th2- and Thl-treated groups (P =
0.195). In contrast, cystemustine with or without BNAG treat-
ments produced a lower volume than control (P = 0.003 for Th3
and Th4, and P < 0.001 for ThM). On day 43, the tumour volumes
were different between the Th3- and Th4-treated groups, but not
significantly (P = 0.235). The Th5-treated group had significantly
smaller tumour volumes than the Th4-treated group (P = 0.002).
No toxicity was observed for treatments ThI, Th2 and Th3. The
non-lethal toxicities of Th4 and Th5 were equal, with a mean
maximum body weight loss close to 8%. Moreover, the loss of
body weight kinetics was closely similar (Figure 2B).
DISCUSSION
The results described here clearly show that the administration of
the water-soluble MGMT inhibitor BNAG enhances the thera-
peutic index of cystemustine, a CENU developed in our labora-
tory. In previous work, we have reported that BNAG is able to
potentiate the efficiency of CENU on human melanoma cells in
vitro and in vivo (Cussac et al, 1994a). In vivo, we have shown
an enhancement of the tumour growth-inhibitory effect and of
cystemustine treatment toxicity by BNAG.
Here, we quantified this toxicity increase by studying the
lethality of different treatments by cystemustine or BNAG alone
British JournalofCancer (1997) 76(9), 1157-1162 0 CancerResearch Campaign 1997CENUpotentiation by 06-benzyl-N2-acetylguanosine 1161
Table 3 Effects of cystemustine and BNAG combination at low dose in nude female mice bearing M4Beu tumour cells
Treatment Tumour volume at day 29 Tumour volume at day 43 Maximum body-weight loss (% day 1)
mean ± s.d. (mm3) mean ± s.d. (mm3) (limit values)
(statistical significance) (statistical significance) (statistical significance)
Thl 553 ± 118 None
(S4 )
Th2 330± 111 None
(NS,; NS4)
Th3 146 ± 34 304 69 None
(S,**; NS4) (NS4)
Th4 75 ± 22 166 ± 58 7.8 (2.6-13.9) on day 9 or 12
(S,***)
Th5 26 ± 4 26 ± 5 7.9 (0-13.2) on day 9 or 12
(Si,***; NS4) (S4*) (NS,)
Eight mice per group were treated on days 1, 5 and 9 after M4Beu cells inoculation by a single i.v. injection of sodium chloride 0.9% (Thl), BNAG 40 mg kg-'
(Th2), cystemustine 15 mg kg-' (Th3), cystemustine 21.6 mg kg-' (Th4), and BNAG 40 mg kg-' with cystemustine 15 mg kg-' (Th5). Statistical analysis was
performed according to the Mann-Whitney U-test for tumour volume and body weight loss. (N)S1, (no) significant difference compared with Thl. (N)S4, (no)
significant difference compared with Th4. (*P < 0.05, **P < 0.01, ***P < 0.001)
or in combination. The i.p. route was chosen to permit high-dose
injection. Associated with a 40 mg kg-' dose ofBNAG, cystemus-
tine toxicity is increased by a factorclose to 1.44 for all doses. This
result demonstrates that the toxic effect of cystemustine may be
improved linearly by BNAG. When we used cystemustine at its
maximal-tolerated dose in association with increasing dose of
BNAG, toxicity was dose dependent and LD50 was obtained with a
260 mg kg-' dose. Thus, a well-tolerated dose of CENU is poten-
tially lethal when the main mechanism of resistance (MGMT) is
depleted. The risk of overdose may be the main limit with the
clinical use ofa more efficient MGMT inhibitor in vitro.
BNAG alone does not display general signs of toxicity up to
640 mg kg-'. Higherdoses were nottested because ofthe difficulty
in dissolving larger amounts of BNAG. Thus, additional intrinsic
toxicity by adjuvants may be avoided with BNAG.
Haematological toxic effects are dose limiting with CENUs and
related methylating agents (Weiss and MacDonald, 1981).
Toxicological studies of 1,3-bis(2-chloroethyl)-1-nitrosourea and
BG combination single-i.v. dose treatments on mice and dogs
show a dramatic increase of CENU myelosuppression by BG in
both species (Page et al, 1994; Rodman et al, 1994). Here, we
detected no external sign of acute haemototoxicity, such as
petechia, but further work is in progress to test the haematological
effect ofour combination.
To assess the efficiency of isotoxic i.v. doses of cystemustine
alone or in combination with BNAG, we chose a previously
described experimental model (Cussac et al, 1994a) with repetitive
i.v. injections on days 1, 5 and 9 after cell inoculation. We found a
linear dose-effect relationship between cystemustine toxicity and
BNAG dose in the i.p. results. The two doses of BNAG used (40
and 50 mg kg-') show that the ratio of 1.44 between isotoxic doses
of cystemustine, alone or in combination, was conserved in both
cases, confirming our suggested low risk ofoverdose with BNAG.
Regarding pharmacological effects, BNAG alone showed no
effect on tumour growth, consistent with its lack of cytotoxicity in
vitro, as previously described (Cussac et al, 1994a). Tumour growth
delay was observed with cystemustine alone but no significant
dose-effect was demonstrated with the different low doses tested.
Only the 27 mg kg' dose showed an improvement of the tumour
growth inhibition with respect to the others. This result illustrates
the limited efficiency ofCENUs towards Mer+ tumour cells.
However, for both sets of isotoxic doses, we observed an
increased tumour growth delay for the combination treatment. We
chose a simultaneous i.v. injection of BNAG and cystemustine,
according to BNAG pharmacokinetic characteristics in the mouse
(Cussac et al, 1994a). As BNAG is rapidly distributed from blood
to tissues (distribution half-life = 13 min), we assumed that
cellular uptake of BNAG would be achieved, and MGMT inhibi-
tion occurring before cystemustine would be able to react with its
target. The tumour growth inhibition obtained with the combina-
tion supports this assumption. Hence, BNAG is the first MGMT
inhibitor to display the ability to be effective as an adjuvant treat-
ment with CENU after simultaneous administration by the i.v.
route. Combination treatment of BNAG with other CENUs is
conceivable and we are currently testing such combinations.
BNAG appears to be a good candidate for adjuvant treatment
with CENUs. It offers four main advantages: (1) the absence of
intrinsic toxicity; (2) linearity of its effect on toxicity, (3) relative
weak activity ofBNAG compared with BG for MGMT inhibition,
limiting the risk ofoverdose in the adjuvant treatment; and (4) the
possibility of simultaneous i.v. injection with associated CENU.
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